| Product Type | Impurity Standards |
| CAT. No. | MRL-E25003 |
| CAS. No. | 1062122-63-7 |
| Mol. Formula | C53H83NO14 |
| Mol. Weight | 958.2 |
| Synonyms | Everolimus 19-Ene Open-Ring Impurity ; seco Everolimus |
| Chemical Name | (2S)-1-[[(2R,3R,6S)-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxodocosa-3,5,7,15,19-pentaen-1-yl]-3-methyloxan-2-yl](oxo)a |
| HSN Code | 38229010 |
| Country of Origin | India |
| Stock Status | Custom Synthesis |
Everolimus EP Impurity B with CAS No: 1062122-63-7 is an impurity standard of Everolimus. Everolimus is an immunosuppressive medication used in transplant medicine and oncology. As an inhibitor of the mammalian target of rapamycin (mTOR), everolimus interferes with cell signaling pathways involved in the regulation of cell growth, proliferation, and angiogenesis. In transplant medicine, everolimus is often used in combination with other immunosuppressive drugs to prevent organ rejection in kidney and liver transplant recipients. In oncology, everolimus has been approved for the treatment of various cancers, including advanced kidney cancer, breast cancer, and certain types of neuroendocrine tumors. Buy high quality Everolimus EP Impurity B from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of Everolimus EP Impurity B